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 Introduction 
 In epilepsy, 3 prognostic groups are generally consid-
ered: (1) spontaneous remission (20–30%) as seen in be-
nign epilepsy with centrotemporal spikes or childhood 
absences; (2) remission on antiepileptic drugs (AEDs) 
(20–30%) as occurs in most focal epilepsy and myoclonic 
juvenile epilepsy syndromes; (3) persistent seizures under 
AEDs (30–40%) among which refractory epilepsy is in-
cluded  [1] . Clinical and EEG predictive factors of refrac-
toriness are red flags in the context of epilepsy manage-
ment and should be thoroughly checked in every epilep-
tic patient. A prompt diagnosis of refractoriness is of 
paramount importance for a timely selection of patients 
for surgery. If the epileptogenic zone cannot be resected, 
palliative procedures should be considered such as vagal 
nerve stimulation, callosotomy, ketogenic diet or multi-
ple subpial transections. Vagal nerve stimulation and a 
ketogenic diet achieve a chance of seizure improvement 
comparable to using a new AED. A better understanding 
of the mechanisms of refractoriness might contribute to 
the development of new, more effective AEDs. Refractory 
patients show an increased risk of psychosocial, psychi-
atric and medical morbidities that should be readily ad-
dressed to ensure a better quality of life  [2] . This review 
aims to be a comprehensive clinically oriented overview 
of refractory epilepsy, and addresses the following topics: 
concepts, predictive factors, diagnosis, treatment, natu-
ral history, mechanisms and treatments under investiga-
tion.
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 Abstract 
 About one third of patients with newly diagnosed epilepsy 
do not achieve seizure control despite medical therapy and 
should be assessed in detail to confirm the diagnosis, to de-
termine the epilepsy syndrome and to plan treatment strat-
egy. Refractory epilepsy is established when there is inade-
quate seizure control despite using potentially effective 
antiepileptic drugs (AEDs) at tolerable levels for 1–2 years, 
and excluding nonepileptic events and poor compliance. An 
overview of patient management in everyday clinical prac-
tice is given. Risk factors for refractoriness include (1) gener-
alized epilepsy with lesions; (2) focal epilepsy with hippo-
campal sclerosis, cortical dysplasia or hemorrhages; (3) early 
epilepsy onset; (4) high seizure frequency; (5) absence of re-
sponse to the first 2 AEDs; (6) high frequency of interictal 
spikes, and (7) multifocal spikes. The efficacy of surgery 
ranges from curative (resection) to palliative (vagus nerve 
stimulation, callosotomy, multiple subpial transections) de-
pending on the epilepsy syndrome and etiology. Using a 
new antiepileptic drug benefits about one third of patients. 
Refractoriness is constitutive in most patients and shows a 
progressive or remission-relapse course in others. As the 
transporter and target hypotheses do not entirely explain 
refractoriness, other hypotheses are emerging. New treat-
ments under investigation are described. 
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 Concepts of Refractoriness 
 Different definitions of refractoriness emerge de-
pending on the context. All are based on the 3 main com-
ponents of intractability: number of AEDs previously 
taken, frequency of seizures and duration of noncon-
trolled epilepsy  [3] . In investigational studies, criteria of 
refractoriness include: (1) absence of response to 2 AEDs 
tolerated at reasonable doses; (2) minimum frequency of 
seizures (e.g. 1 seizure per month) to be considered re-
fractory or the duration of minimum remission (e.g. 6–
12 months) to be qualified as nonrefractory, and (3) du-
ration of 1 year to 1 decade of noncontrolled epilepsy. 
Depending on the criteria applied, the frequency of re-
fractory epilepsy varies from 10 to 37.5%  [4–6] . A flexible 
scale of refractoriness has been developed for clinical use 
and classifies epilepsy as potential (no seizure freedom 
with AEDs taken less than 1 year and predictive factors 
for refractoriness), probable (no seizure freedom more 
than 1 year with at least 2 AEDs) or definitely refractory 
(catastrophic epilepsy or no freedom of seizure for more 
than 1 year after 5 years of treatment with at least 3 
AEDs) depending on the duration of epilepsy and medi-
cal treatment, seizure control and number of AEDs used 
 [7] . A subclassification of refractoriness as acceptable or 
inacceptable was also included, taking into account the 
patients’ impression of the impact of epilepsy (seizures, 
comorbidity and adverse effects of AEDs) on their qual-
ity of life (e.g. a patient with acceptable refractory epi-
lepsy presenting infrequent nocturnal seizures may 
 become definitely refractory with the occurrence of di-
urnal generalized tonic-clonic seizures affecting em-
ployment, education and driving). Potential refractory 
epilepsy may evolve to probably refractory depending on 
the duration of AED intake and the influence of predic-
tive factors of refractoriness  [7] .
 Predictive Factors of Refractoriness 
 Epileptic syndrome, response to AEDs, age and sei-
zure frequency at epilepsy onset are clinical determinants 
for predicting future refractoriness.
 A long follow-up study (30 years) of children with ep-
ilepsy showed that only 13% of all patients with idio-
pathic generalized epilepsy, and no case with idiopathic 
partial epilepsy, were refractory. In contrast, 78% of pa-
tients with altogether rare symptomatic generalized epi-
lepsy and 49% of patients with the much more common 
symptomatic partial epilepsy were not in remission  [8] . 
Typical refractory generalized epilepsy of pediatric ages 
are the Ohtahara syndrome, early myoclonic encepha-
lopathy (neonatal period), West syndrome, Dravet syn-
drome (infancy) and Lennox-Gastaut syndrome (early 
childhood)  [9] . In focal epilepsy, hippocampal sclerosis, 
cortical dysplasia and hemorrhage are associated with 
refractoriness  [10] . The localization of the epileptogenic 
zone also seems to play an important role in refractori-
ness. The temporal lobe is probably the most epilepto-
genic area as it is the most common of the focal epilepsy 
syndromes  [11] and kindling is easily elicited by stimula-
tion of the amygdala  [12] . The striate cortex, namely the 
fourth layer, was also proved to be highly epileptogenic 
 [13] . The motor (hand and face area) and sensorimotor 
cortices are other areas with low seizure thresholds 
 [14] .
 Absence of seizure freedom when 2 past AEDs proved 
inefficient is a crucial predictor of refractoriness  [4] . A 
recent studied added that refractoriness is a continuum 
and showed the benefit of adding a previously not used 
AED even when 2–5 past AEDs were not effective. Sei-
zure-free rates decreased from 61.8% for the first AED to 
41.7% and 16.6% after 1 and 2–5 past AEDs proved inef-
ficient. After 6 AEDs, absolute refractoriness (0% seizure 
free) was found  [15] .
 A younger age at onset of epilepsy predicts refractori-
ness  [16] . Seizures in the immature brain of a child may 
result in nonpruning of neurons and contribute to high 
numbers of gap junctions, which leads to abnormal con-
nectivity, the hyperconnected cortex  [17] .
 High seizure frequency (more than 1 seizure per 
month) occurring soon after the diagnosis of epilepsy ei-
ther before or after treatment onset correlates with re-
fractoriness in the short term (2–4 years) and long term 
(30–35 years)  [6] . Depression has recently also been as-
sociated with lack of response to AEDs  [18] . Neurobio-
logical processes that underpin depression may interact 
with those producing seizures to increase the extent of 
brain dysfunction and thereby the likelihood of develop-
ing pharmacoresistant epilepsy  [18] .
 Electroencephalography is useful for predicting re-
fractoriness. The quantity of interictal spikes is predic-
tive of severity in temporal lobe epilepsy  [19] . Oligospik-
ers, patients with temporal lobe epilepsy with less than 1 
spike per hour, correlate with less severe epilepsy  [20] . In 
addition, some studies describe the association between 
multifocal spikes and intractability  [21] .
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 Diagnosis of Refractory Epilepsy 
 Firstly it is mandatory to exclude false refractoriness 
related to nonepileptic seizures, inadequate AEDs, non-
compliance and seizure-precipitating factors. Video-EEG 
monitoring is an essential tool in this process, aiming to 
perform a differential diagnosis of paroxysmal events 
and a correct classification of seizures and epileptic syn-
dromes. An estimated 20% of patients referred to com-
prehensive epilepsy programs for medically refractory 
‘seizures’ do not have epilepsy  [22] . Nonepileptic events 
more frequently found include cardiovascular syncopes, 
sleep diseases and psychogenic events  [23] . Correct clas-
sification of seizure type and epileptic syndrome is man-
datory for selecting the adequate AED  [24] . Selected gen-
eralized forms of epilepsy may be aggravated by some 
AEDs  [24] . Studies have reported that approximately 30–
50% of patients with epilepsy do not comply with their 
prescribed AED therapy  [25] . Nonadherence was proved 
to be associated with a more than threefold increased risk 
of mortality, a significantly higher incidence of emergen-
cy department visits, hospital admissions, motor vehicle 
accident injuries, and fractures than during periods of 
adherence  [25] . Finally, sleep irregularities, alcohol 
abuse and specific factors for reflex epilepsy should be 
excluded.
 The second step in the diagnosis of refractory epilepsy 
is to confirm refractoriness. This definition is generally 
accepted when there is inadequate control of seizures de-
spite at least 2 potentially effective AEDs (mono- or poly-
therapy) taken in tolerable doses  [26] . Refractory patients 
should be referred to an epilepsy service for further diag-
nostic evaluation, optimization of pharmacotherapy, and 
consideration of other therapies such as epilepsy surgery. 
The evaluation of refractory patients for epilepsy surgery 
should consider the following clinical issues: (1) adequate 
control of seizures should be considered by the patient 
(e.g. some patients with 1–2 seizures/year prefer surgery 
for professional or social reasons while others do not feel 
that seizures have a severe impact on their quality of life) 
and balanced by the doctor in relation to the probability 
of successful surgery success compared to AED treat-
ment (e.g. temporal lobe epilepsy with hippocampal scle-
rosis has such a high probability of seizure freedom that 
surgery should be considered even with low seizure fre-
quency, in contrast to an extratemporal epilepsy with no 
MRI lesion where only a high frequency of seizures could 
justify surgery); (2) although refractoriness is generally 
considered following 1–2 years of noncontrolled epilepsy, 
epilepsy surgery may be performed earlier in the case of 
catastrophic epilepsy or a high chance of surgical cure, or 
later in case of low seizure frequency or a very low chance 
of successful surgery. 
 Treatment of Refractory Epilepsy 
 Defining epilepsy refractory to medical treatment im-
plies considering surgery. The prognosis will differ as a 
function of the epilepsy syndrome and etiology involved 
and depending on whether the intervention is curative or 
palliative. In addition, other interventions such as a keto-
genic diet and the contribution of AEDs should not be 
disregarded.
 Surgery 
 Resective surgery is based on removal of the entire ep-
ileptogenic area without causing a permanent neurologi-
cal deficit. The localization of the epileptogenic zone in 
focal epilepsy is typically based on seizure semiology, in-
terictal and ictal EEG findings, as well as FDG-PET, 
SPECT and MRI lesions  [27] . Focal epilepsy with a lesion 
not adjacent to the eloquent cortex and concordant with 
semiology, ictal EEG, interictal EEG and PET/SPECT 
may be removed based solely on surface evaluation. In the 
case of focal epilepsy without a lesion, a lesion adjacent to 
an eloquent cortex or if there is no concordance between 
the different zones, invasive monitoring is recommended 
 [27] . 
 More than half of the procedures in surgical epilepsy 
programs are anterior temporal lobe resections  [28] . Me-
sial temporal lobe epilepsy associated with hippocampal 
sclerosis is the most common form of focal epilepsy, with 
around 60% of the patients having temporal resection. 60–
70% of the patients are free of seizures at 1–2 years of fol-
low-up  [29, 30] and only 58% are seizure free at 10 years 
 [31] . The outcome of surgery greatly depends on the under-
lying cause of epilepsy. Patients with vascular malforma-
tions, low-grade tumors, dysembryoplastic neuroepithe-
lial tumors, and cystic lesions have surgical outcomes that 
are as good as or better than those of patients with hippo-
campal sclerosis  [32] . Cortical dysplastic lesions and post-
traumatic gliosis have a 3 times higher rate of recurrence, 
indicating a risk of incomplete resection or additional epi-
leptogenic areas  [33] . Predictors of short-term outcome 
(duration of epilepsy, age at onset, age at surgery, unilat-
eral spikes, preoperative secondarily generalized tonic-
clonic seizures, and preoperative seizure frequency) do not 
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predict long-term outcome in patients with temporal lobe 
epilepsy associated with hippocampal sclerosis  [34] . 
 Extratemporal lobe surgery for focal epilepsy accounts 
for less than half of all epilepsy operations  [35] . In frontal 
lobe epilepsy surgery, the probability of becoming seizure 
free is 55.7% at 1 year, 45.1% at 3 years, and 30.1% at 5 
years  [36] . The subset of patients with favorable prognos-
tic factors – an MRI lesion restricted to one frontal lobe, 
complete resection, and a regional or lateralized ictal 
scalp EEG pattern – show a seizure-free outcome ap-
proaching that seen after temporal lobectomy, with 50–
60% being seizure free at 3 years. Regarding etiology, pa-
tients with low-grade tumors have the best outcome 
(62%), followed by patients with MRI malformations of 
cortical development (52%).
 Hemispherectomy or hemispherotomy has been re-
ported to be beneficial (improvement of seizure frequen-
cy and developmental quotient) in children with cata-
strophic hemispheric epilepsy of diverse etiologies such 
as malformations of cortical development, Rasmussen’s 
encephalitis, Sturge-Weber syndrome, and remote vas-
cular insults  [37] .
 Palliative Interventions 
 Complete seizure control is not a realistic objective for 
some patients, but useful palliation can sometimes be 
achieved with techniques such as vagal nerve stimulation, 
corpus callosotomy, and multiple subpial transections.
 Vagal nerve stimulation is indicated in adults with fo-
cal epilepsy with no indication of surgery or who had un-
dergone surgery without success and in intractable gen-
eralized symptomatic epilepsy. It might also be effective 
in children with drop attacks and Lennox-Gastaut syn-
drome. On average, a 50% reduction in seizure frequency 
has been reported in about one third of patients, the same 
range of expected benefit as in trying a new AED with the 
advantage of lower adverse effects. However, seizure free-
dom is rare  [38] . Corpus callosotomy is mostly used in 
patients with Lennox-Gastaut syndrome to reduce the 
number of disabling drop attacks  [39] . Multiple subpial 
transections use vertical incisions in the gray matter at 
4-mm intervals to limit propagation of epileptic activity 
within eloquent cortex and to reduce seizure spread with-
out disturbing functional integrity. It is reported to 
achieve a significant seizure reduction  [32] . A ketogenic 
diet, i.e. high in fat and low in carbohydrate, is mainly 
used in pediatric patients (due to tolerability) as second-
line treatment in focal nonsurgical refractory and gener-
alized symptomatic epilepsy. A recent randomized con-
trolled trial showed a reduction in seizure frequency in 
more than 50% in 38% of children with drug-resistant 
epilepsy  [40] .
 In chronic epilepsy (more than 5 years), the addition 
of a new AED provided a seizure freedom of 17% and a 
50–99% seizure reduction of 25%. For those who did not 
respond to the first trial, a similar benefit might be ex-
pected for at least 2 more trials. At the end, 28% of the 
patients were seizure free  [41] . The application of a sys-
tematic protocol to the treatment of refractory epilepsy 
using a new AED might improve seizure control in a sub-
stantial proportion of cases. The nihilistic view that in-
tractability is inevitable if seizure control is not obtained 
within a few years of the onset of therapy is incorrect  [41] . 
Zonisamide, 100–400 mg i.d., levetiracetam, 1,000–3,000 
mg i.d., lamotrigine, 300–500 mg i.d., topiramate, 300–
1,000 mg i.d., and gabapentin, 600–1,800 mg i.d., have 
demonstrated efficacy (evidence level A) as add-on ther-
apy in patients with refractory focal epilepsy  [42] . Even 
though the methodology was similar in all studies, it is 
not possible to determine the relative efficacy from com-
parison of outcomes because the populations differed, 
and some drugs were not used in maximum doses where-
as others appear to have been administered above the ide-
al dose. For essentially all drugs, efficacy as well as side 
effects increased with increasing doses  [42] .
 In refractory epilepsy, it is convenient to perform a 
systematized management of AED: (1) increase until the 
maximum tolerable dose; (2) if no response, replace the 
AED, if there is a partial response, add another AED 
which should be chosen based on the mechanism of ac-
tion of the first AED (e.g. lamotrigin and valproate are 
synergic), its efficacy and adverse effects  [24] .
 Temporal Pattern of Refractoriness 
 First, based on partly prospective and hospital-based 
observations in adult-onset epilepsy, it has been claimed 
that in most cases pharmacoresistance is constitutive, i.e. 
it is fully developed before the first seizure or at least be-
fore the start of AED treatment  [4] .
 There is emerging evidence from one retrospective 
study of a highly selected group of patients undergoing 
temporal lobe surgery that, at least in some patients with 
easily treatable epilepsy, pharmacoresistance requiring 
surgery developed years later in the course of their epi-
lepsy  [43] . If prospective studies confirm these findings 
and the underlying mechanisms behind these associa-
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tions are elucidated, interventions may be envisaged that 
might interrupt such a process and some day prevent 
some forms of epilepsy from becoming intractable  [44] .
 Finally, the most controversial hypothesis claims that 
drug resistance may remit and reappear in the course of 
epilepsy or its treatment. Some authors have described an 
intermittent pattern where active epilepsy is interrupted 
by periods of remission  [45] . However, a competing ex-
planation is that the improvement after initial failure to 
respond may also be related to changes in AED use, for 
example the introduction of newer drugs, over the years 
 [44] .
 Natural History 
 Sillanpaa and Schmidt  [46] have studied a cohort of 
childhood-onset epilepsy for 37 years and found that 33% 
of patients had refractory epilepsy whereas 67% were sei-
zure free. Most of the refractory patients (27/47 patients) 
presented as claimed in the constitutive hypothesis of re-
fractoriness from the onset of epilepsy. In the remaining 
refractory patients (20/47 patients), refractoriness devel-
oped later in the course of epilepsy, according to the pro-
gressive hypothesis of refractoriness. Although it is reas-
suring that a total of 67% of patients were able to enter 
terminal remission, it took more than a decade in many 
patients, particularly in those with mental retardation 
and symptomatic epilepsy. A relapse-remission course 
was seen in 20% of patients while a remission course from 
the onset of epilepsy was seen in 48% of patients either in 
the first year (16%) or afterwards (32%)  [46] . Further, this 
study showed that in patients with childhood-onset epi-
lepsy, long-term seizure outcome cannot be reliably pre-
dicted by the response at the onset of treatment  [46] . This 
suggests that before initiation of therapy many seizures 
may be the consequence, rather than the cause, of the un-
derlying physiological mechanism responsible for refrac-
toriness in this group of patients and corroborates the 
notion that antiseizure drugs do not have a true antiepi-
leptic effect.
 Mechanisms of Refractoriness 
 The transporter and target hypotheses are the most 
commonly cited mechanisms of refractoriness, although 
they cannot yet fully explain refractoriness.
 According to the drug transporter hypothesis, re-
stricted access of AEDs to the seizure focus is the result 
of either locally increased expression of drug transporter 
proteins, most notably P-glycoprotein (P-gp), encoded by 
the  ABCB1 gene, or a genetic variation in  ABCB1 result-
ing in increased transporter activity.
 The proposed mechanism suffers from a lack of evi-
dence that many clinically used AEDs are substrates for 
human P-gp or any other known human blood-brain 
barrier efflux transporter  [47] . The transporter hypoth-
esis has also failed to receive support from recent genetic 
association studies, including a meta-analysis that failed 
to replicate early reports of an association between poly-
morphisms in the  ABCB1 gene and drug resistance  [48] .
 According to the target hypothesis, epilepsy pharma-
coresistance occurs when intrinsic (genetic) or acquired 
(disease related) changes in drug targets make them less 
sensitive to AEDs. Recent studies have provided evidence 
of reduced sensitivity to carbamazepine in brain tissue 
from patients who were clinically unresponsive to carba-
mazepine and underwent resective surgery  [49] . Howev-
er, it is unknown whether pharmacodynamic insensitiv-
ity in these tissues extended to AEDs with different 
mechanisms of action or even to other AEDs that target 
sodium channels. A polymorphism in the  SCN1A gene 
encoding Nav1.1 sodium channels has been described, 
which associates with the use of higher doses of carba-
mazepine and phenytoin, suggesting that there is reduced 
sensitivity to these drugs  [50] . However, this polymor-
phism is unlikely to influence sensitivity to AEDs that do 
not act through sodium channels. The acquired version 
of the target hypothesis proposes that the pharmacody-
namic sensitivity of the AED target is modified by the 
disease state  [51] . There are many examples of changes in 
the activity of voltage-gated and neurotransmitter-acti-
vated ion channels in acquired epilepsy models, some of 
which lead to reduced responsiveness to AEDs  [52] . How-
ever, there is no evidence that the efficacy of AEDs acting 
on different targets is similarly affected.
 An alternative mechanism for explaining refractori-
ness was suggested – the intrinsic disease severity  [53] . 
This hypothesis claims that there are differences in in-
herent epilepsy severity reflected in the frequency of sei-
zures in the early phase of epilepsy (the single most im-
portant factor associated with prognosis). Possibly, com-
mon neurobiological factors may underlie both epilepsy 
severity and drug refractoriness. These authors suggest 
that to advance in the understanding and therapeutic 
management of refractory epilepsy, it is crucial to iden-
tify biomarkers which define the most severe forms of 
epilepsy. Unfortunately, there are few studies on the con-
tribution of genetics to the severity of epilepsy  [53] .
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 Treatments under Investigation 
 Polymers, electrical brain stimulation and prediction 
of seizures may be available in the future for treating pa-
tients with refractory epilepsy. Cell transplantation and 
gene therapy, although holding great promise, are still far 
from routine clinical use  [54] .
 Polymers containing AEDs consist of 2- to 3-mm mi-
crospheres that might be placed near the epileptogenic 
zone. Advantages include: (1) new AEDs could be used 
including those which do not cross the blood-brain bar-
rier or show systemic toxicity; (2) they may be useful 
when the epileptogenic zone is near eloquent cortex; (3) 
they prevent noncompliance  [55] . Implanting wafers im-
pregnated with chemotherapeutic agents into the resec-
tion cavity results in prolongation of survival without an 
increased incidence of adverse events  [56] . Studies in an-
imals have been promising as the application of polymers 
containing phenitoin to the epileptogenic zone in mice 
has reduced epileptogenic indexes  [57] .
 Electrical brain stimulation is still not accepted as a 
routine treatment for epilepsy, partly because there is no 
consensus regarding the better region to stimulate and in 
what type of seizure it is most effective. The epileptogen-
ic zone and the centromedian or anterior nuclei of the 
thalamus seem to be the most effective targets for electri-
cal stimulation  [58] . The efficacy seems to be similar to 
vagal nerve stimulation which has a lower risk and less 
comorbidity  [58] . This intervention is thus unlikely to be 
routinely used in the future.
 Finally, a seizure detector coupled with a trigger AED 
infusion pump has been developed with success in the 
mouse  [59] . Research has also been done in predicting 
seizures  [60] . Hopefully, in the future a device may pre-
dict seizures and automatically administer AEDs to pre-
vent them from occurring.
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